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Competitive ELISA for serodiagnosis of bluetongue: a refinement A. Afshar, G. C. Dulac, C. Dubuc, J. E. Pearson, G. A. Gustafson Several group specific monoclonal antibody (MAb)-based enzyme-linked immunosorbent assays (ELISAs) have been developed for the detection of antibodies to the group-specific antigens of bluetongue virus (BTV). In 1984, a blocking (B) ELISA was described in which the immobilized BTV antigen was first reacted with a test serum and then with a BTV group-specific MAb (3.17.A3) from Pirbright Laboratory (PL). 5 In 1987, a competitive (C) ELISA was developed in which the test serum and the same MAb (3.17.A3) were reacted simultaneously to compete for BTV antigen coated on polystyrene plates. 3 The C.ELISA was more sensitive and specific than the agar-gel immunodiffusion, the modified complement fixation, the plaque neutralization, and the in-direct ELISA tests. 4 Several other laboratories have adopted a competitive or a blocking format, using PL MAb 3.17.A3 or other MAbs, and have clearly demonstrated the advantages of these assays for the detection of group-specific antibodies to BTV. [8] [9] [10] 13 In a recent study on several coded panels of bovine sera, both C.ELISA and B.ELISA demonstrated comparable performance. However, the advantage of the C.ELISA over the B.ELISA format is that it requires less time to perform. 1 For the past 4 years, Agriculture Canada's Animal Diseases Research Institute, Nepean (ADRI), and USDA's National Veterinary Services Laboratories, Ames (NVSL), have extensively applied the C.ELISA, using the PL MAb 3.17.A3, for serologic surveys and for certification of animals prior to From the Animal Diseases Research Institute, Agriculture Can-exportation and importation. The assay is also used for monada, PO Box 11300, Station H, Nepean ON K2H 8P9, Canada itoring cattle at artificial insemination (AI) centers and for (Afshar, Dulac, Dubuc) . and the National Veterinary Services Lab-sentinel cattle herds used in the Okanagan Valley as an im-, oratories, USDA-APHIS, PO Box 844, Ames, IA 50010 (Pearson, BTV, a negative cutoff value of 40% inhibition (PI) was established. 3 Following an extensive field validation, 4 this threshold was raised to a value of 50 PI.
As part of the BT monitoring program in Canada, all samples giving PI values ≥ 50 are tested routinely in the microtiter serum neutralization (MTSN) test 12 to determine which of anti-BTV serotypes 2, 10, 11, 13, and 17 are responsible for the C.ELISA reaction. 7 In the past year, from 15,000 field samples from cattle tested by C.ELISA at ADRI (n = 12,500) and NVSL (n = 2,500) a relatively small portion (0.33%) of sera have resulted in values above the 50 PI threshold, with subsequent negative results in the MTSN tests. In an attempt to define more accurate criteria for classification of sera by the C.ELISA, the C.ELISA/MTSN discrepant samples generated by both laboratories were tested with other ELISA tests. This paper reports the test results of 50 samples using the standard C.ELISA with noninactivated and heat-inactivated serum and MAb 3.17.A3, the C.ELISA with noninactivated serum and a BTV group-specific MAb 8.A3.B-6; 2,6,9 and the B.ELISA with noninactivated serum and MAb 3.17.A3. 5 A total of 50 MTSN-negative/C.ELISA-positive sera with PI values >50 from 15,000 bovine field samples tested in 1991-1992 were included in this study. The sera consisted of 37 samples collected in BT-free areas in Canada and 13 samples received from NVSL. Each serum sample was tested by C.ELISA-I, 4 -II, and -III and by B.ELISA. 5 Heat-inactivated (56 C/30 minutes) samples were tested only in the C.ELISA-II, using MAb 3.17.A3, originally developed by Dr. John Anderson 5 and obtained from Pirbright Laboratory, UK. The second MAb, identified as 8A.3B-6, was originally developed by Drs. J. A. Appleton and G. A. Letchworth and reported in 1983, 6 was utilized in the C.ELISA. 2,9 The hybridoma (CRL 1875) producing the MAb 8A.3B-6 was obtained from the American Type Culture Collection (ATCC), Rockville, Maryland, and cultured according to a method described previously, 11 and the cell culture fluids were used in the C.ELISA-III. The BTV antigen used in the C.ELISAs and B.ELISA was prepared from baby hamster kidney-21 cells infected with BTV serotype 11 as described previously. 11 In the C.ELISA-I and -II, samples that inhibited ≥ 50% were considered positive; in the C.ELISA-III and B.ELISA, samples that inhibited 240% were considered positive. The results of the 3 C.ELISAs and 1 B.ELISA for 50 serum samples that were classified as positive by the standard C.ELISA and negative by the MTSN are shown in Table 1 . Relative to the standard C.ELISA-I and based on the negative cutoff point of 50 PI, heat inactivation of sera procedure (C.ELISA-II) reduced the number of the C.ELISA-I-positive sera from 50 to 28. However, in the B.ELISA format, in which the same MAb, 3.17.A3, was used, only 7 of 50 samples were classified as positive. The best performance for reducing the number of false positives, relative to MTSN, was recorded by the C.ELISA-III, in which the test sample was not inactivated and the ATCC MAb, 8A.3B-6, was used. There were only 3 samples classified as false positive by the C.ELISA-III. Seven of 50 MTSN-negative sera tested by the C.ELISA-I had values >70 PI. These consisted of 5 samples with values 574 PI and 1 sample with a value of 90 PI. The comparative values of these highly reactive sera, as measured by all the ELISAs, are shown in Table 2 . Heat inactivation (C.ELISA-II) did not change the status of these 7 samples. However, all 7 samples were negative in the C.ELISA-III and the B.ELISA with the exception of 3 samples ( Table 2 ). The other 43 MTSN negative sera generally had values for the C.ELISA-I ranging from 50 PI to 70 PI. All of these sera were negative when tested by the C.ELISA-III (except 3 samples) and B.ELISA (except 7 samples).
These results support the recommendation that any serum sample giving a value 250 PI in the C.ELISA-I should be retested by the 2 other auxiliary assays, the C.ELISA-III and the B.ELISA. If a sample gives a value of >40 PI in any of these auxiliary assays, then a confirmatory MTSN should be carried out to establish the serotype specificity of the antibodies.
6.
We have described some auxiliary assays for the confirmation of positive C.ELISA-I results. The testing of samples with values of 150 in the C.ELISA-I by at least 1 of the other ELISA formats, a competitive assay using the ATCC MAb and/or a blocking assay using the Pirbright MAb, reduces the number of sera referred for confirmatory MTSN testing.
Immunohistochemical detection of CD3 antigen (pan T marker) in canine lymphomas
Luis Ferrer, Dolors Fondevila, Rosa Rabanal, Jordi Tarres, Antonio Ramis Lymphoma, with an incidence of 24 cases per 100,000 dogs, is the third most common neoplasia in dogs. 5 Although in recent years considerable advances have been made in the diagnosis and treatment of canine lymphoma, the histogenesis and the immunologic characteristics of the proliferating cells are not completely understood. Some studies using immunofluorescence techniques or cytofluorographic analysis reported that most canine lymphomas originate from B lymphocytes, although no definitive results were obtained. 7 ' 9 The identification of the immunophenotype of canine lymphomas is important not only for a better understanding of thebiology of this neoplasm but also because some canine im-From the Department of Animal Pathology, Veterinary School, Autonomous University of Barcelona, 08193 Bellaterra, Barcelona, Spain.
Received for publication February 3, 1993. munophenotypes (T-cell lymphomas) have shorter survival times. 7 A wide range of well-characterized reagents directed at human lymphocyte surface markers are used to immunophenotype human lymphomas, but the vast majority of these do not cross-react with canine lymphocyte surface markers? Unfortunately, very few monoclonal antibodies have been developed for dogs, 12, 13, 19 and these monoclonal antibodies only work on frozen tissue and do not react with formalinfixed, paraffin-embedded sections.
Recently, a polyclonal antibody has been developed that is directed against a sequence of the human CD3 molecule that is resistent to formalin fixation and paraffin embedment. 11 The CD3 molecule is associated with the T-cell receptor and transmits the activation signal to the cytoplasm. Extensive studies in human beings have demonstrated that the CD3 molecule is restricted in its expression to T-lym-
